Why is the Cochlear share price in the red today?

Investors continue to sell the stock.

| More on:
A woman leans forward with her hand behind her ear, as if trying to hear information.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Cochlear Ltd (ASX: COH) share price has been volatile in recent months and is now down 4% this year to date.

Shares in the hearing solutions company are currently swapping hands at $286.19 apiece on Thursday, less than 1% in the red.

While the company did not post anything price-sensitive today, it did announce the appointment of a new Chief Financial Officer (CFO).

Here is more on that announcement.

Created with Highcharts 11.4.3Cochlear PriceZoom1M3M6MYTD1Y5Y10YALL1 Sep 202319 Sep 2024Zoom ▾Sep '23Nov '23Jan '24Mar '24May '24Jul '24Sep '24Oct '23Oct '23Jan '24Jan '24Apr '24Apr '24Jul '24Jul '24www.fool.com.au

Cochlear appoints new CFO

Cochlear recently announced the appointment of Sarah Thom as its new CFO, effective 1 January 2025.

Thorn joins Cochlear from BCG, where she served as a Managing Director and Partner.

Cochlear CEO Dig Howitt expressed confidence in Thom's capabilities:

I am delighted to welcome Sarah to Cochlear. Sarah has a unique blend of capabilities in strategy and transformation design and delivery in the health care and medtech sectors. Sarah joins us at an exciting time in Cochlear's growth journey and she will be a valuable addition to the Cochlear executive team.

Thom will begin her transition into the role in November 2024, working closely with the current CFO, Stu Sayers, who will move to his new role as President, Asia Pacific & Latin America.

Long-term outlook for Cochlear shares intact

Cochlear's share price has been under pressure since the release of its FY24 earnings last month. Despite a 15% increase in sales revenue and a 27% jump in profit to $387 million, the results fell at the lower end of the company's guidance.

This missed the market's expectations, with analysts anticipating a profit closer to $397 million.

Investors may have been looking for a stronger performance, particularly after the company raised its guidance in February. Additionally, the company expects profit growth of 6% – 11% in FY25.

Stock prices are often set on expectations, so when expectations are high, even the slightest miss can cause volatility.

But this actually provides opportunities for the patient and intelligent investor who has a long-term view in mind.

So, despite recent market volatility, Cochlear's long-term growth prospects appear to remain intact.

CEO Howitt said Cochlear aims for annual revenue growth of around 10% moving forward.

It also aims to help over 50,000 people with cochlear or acoustic implants in FY25 – hard to argue with the benefit to society here either. It's not all just about the numbers.

The company's core hearing implant business continues to show strong growth, particularly in developed markets.

While emerging markets experienced slower growth in the latter half of FY24, management believes in the long-term potential of these regions.

Foolish takeaway

The short-term weakness in the Cochlear share price might be unsettling for some investors, but the company's long-term strategy outlook can't be ignored.

For patient, long-term investors, this volatility offers the opportunity to allocate to high-quality businesses at more attractive prices.

Time will tell what Cochlear shares will do from here. They are up 10% in the past year.

Should you invest $1,000 in Cochlear Limited right now?

Before you buy Cochlear Limited shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Cochlear Limited wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 9 January 2025

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Cochlear. The Motley Fool Australia has recommended Cochlear. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

With a projected 7% dividend yield, is the Medibank share price a buy?

Investors may receive very healthy dividends from this stock.

Read more »

Healthcare Shares

Guess which ASX 200 stock is jumping to record high on big European news

What is getting investor excited on Friday? Let's see what is happening.

Read more »

Man with rocket wings which have flames coming out of them.
Healthcare Shares

Goldman Sachs tips ResMed shares to rocket 30% to a record high

The broker is feeling very bullish about the sleep disorder treatment company.

Read more »

A bland looking man in a brown suit opens his jacket to reveal a red and gold superhero dollar symbol on his chest.
Healthcare Shares

Why CSL shares could be dirt cheap in 2025

Goldman Sachs sees a lot of value in this blue chip stock.

Read more »

The last piece of the jigsaw being fitted, indicating good news for a share price on merger or acquisition
Healthcare Shares

What will happen to the Sigma share price after the Chemist Warehouse merger?

Morgan Stanley analysts explain the default factor that will support the Sigma share price after the merger.

Read more »

Shot of a young scientist looking stressed while conducting medical research in a laboratory.
Broker Notes

Why this top fundie has a 'loss of confidence' in CSL shares

CSL has a lot of broker support right now but Firetrail has an opposing view on the ASX 200 healthcare…

Read more »

Shot of a senior scientist looking stressed out while working in a lab.
Healthcare Shares

Why did this $1.4 billion ASX 200 healthcare stock just dive 9%?

The market didn't like what this stock had to say this morning...

Read more »

A woman wakes up after sleeping soundly, stretching her arms high sitting in bed.
Healthcare Shares

ResMed shares are up 42% in a year. This shows why they could still be great value

The investing pros at Firetrail forecast another strong year for ResMed shares in 2025.

Read more »